May 7, 2018 / 12:42 PM / 2 months ago

BRIEF-Immune Pharmaceuticals Says Board Will Not Pursue Spin-Off Of Cytovia Unit

May 7 (Reuters) - Immune Pharmaceuticals Inc:

* IMMUNE PHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR ONCOLOGY SUBSIDIARY, CYTOVIA, INC.

* IMMUNE PHARMACEUTICALS INC - COMPANY'S BOARD WILL NO LONGER PURSUE A SPIN-OFF OF ITS ONCOLOGY-FOCUSED SUBSIDIARY, CYTOVIA INC

* IMMUNE PHARMACEUTICALS - DANIEL TEPER HAS RESIGNED AS CEO OF CYTOVIA AND FROM BOARD OF DIRECTORS OF BOTH CYTOVIA AND IMMUNE, EFFECTIVE IMMEDIATELY

* IMMUNE PHARMACEUTICALS INC - CYTOVIA INC HAD BEEN LED BY IMMUNE'S FOUNDER AND FORMER CHIEF EXECUTIVE OFFICER DANIEL TEPER

* IMMUNE PHARMACEUTICALS INC - HAS INITIATED DISCUSSIONS WITH PARTIES POTENTIALLY INTERESTED IN ACQUIRING CERTAIN OF CYTOVIA'S ASSETS

* IMMUNE PHARMACEUTICALS INC - IMMUNE WILL CONTINUE TO FOCUS ITS EFFORTS AND RESOURCES ON DEVELOPMENT OF ITS CORE PROGRAMS, BERTILIMUMAB AND NANOCYCLO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below